129823520720468750_407Shanghai pharmaceutical clarify press reports
Shanghai pharmaceutical clarified newspaper reports, and at the request the SEHK, declared inter alia to clarify things, is not known to cause price declines for any reason. Shanghai pharmaceutical to clarify meaning, the company was not received by the SFC and the stock exchange of Hong Kong on the company's financial or other notice of any investigation into the matter. To clarify
Rift Platinum, Kang Li 70% equity acquisition of pharmaceutical company has completed, and by law in respect of the acquisition, businessRegistration. Kang Li full intellectual property rights in the pharmaceutical with its intangible assets. Due to the company in early 2012, gaining effective control of the Kang Li pharmaceutical, financial report for the first quarter of 2012 will therefore Kang Li pharmaceutical merged into the company's financial statements, in accordance with the applicable accounting standards of the relevant provisions. Clarification
TERA Gold, Wing Road
TERA Power Leveling, international Auditors Price Waterhouse and the territory of the company's Auditor GeneralPWC Zenith, 2011 annual financial report issued by a standard unqualified audit report, while Shanghai New Asia's auditor PricewaterhouseCoopers Zhong Tian 2011 Shanghai New Asia financial report issued by a standard unqualified audit report. The standard unqualified audit reports show, Shanghai New Asia and the company's revenues and profits are in full compliance with applicable accounting standardsLaw records. And to clarify, on Pioneer Shanghai new acquisitions of intangible assets of the company on April 7, 2012 release title for the acquisition of Shanghai New pioneer pharmaceutical company announcements made in official disclosure of intangible assets. As disclosed in the announcement, the acquisition price is based on independent third-party assessment of guardian in the assessment report of the valuation of the assets and to fulfil theRelated programs of State-owned assets assessment for the record. Company believes that the acquisition is fully in line with the territory of China and Hong Kong's regulatory requirements concerning connected transactions, are fair and reasonable and in the interest of the company and its shareholders as a whole. After May 23, the 21st century business Herald reported and some other media, Shanghai pharmaceutical's acquisition of Changzhou Kang Li pharmaceuticals, as well as the companies alleged to 201First quarter 2 Kang Li pharmaceutical merged into the financial statement of the company financial statements present financial fraud company alleges 2011 acquisitions Shanghai New Asia financial fraud company alleged manipulation of its intangible assets on acquisition of Shanghai New pioneer drug price; and about the SFC and the stock exchange of Hong Kong on rumours of the allegations to investigate the company.
Others:
没有评论:
发表评论